Design and analytic validation of BCR-ABL1 quantitative reverse transcription polymerase chain reaction assay for monitoring minimal residual disease

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 33-40

  Jennings, Lawrence J ^a,e   Smith, Frederick A ^a   Halling, Kevin C ^b   Persons, Diane L ^c   Kamel Reid, Suzanne ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ARTICLE; CHRONIC MYELOID LEUKEMIA; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MOLECULAR DIAGNOSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; STANDARD; UNITED STATES;

FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM, RESIDUAL; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856026969     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0136-OA     Document Type: Article

References (30)

1. Bader P, Kreyenberg H, Henze GH, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27(3):377-384.
2. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008; 111(12):5477-5485.
3. Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol. 2009;27(31):5195-5201.
4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-1432. (Pubitemid 37211057)
5. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23): 2408-2417. (Pubitemid 44903745)
6. Jennings L, Van Deerlin VM, Gulley ML. Recommended principles and practices for validating clinical molecular pathology tests. Arch Pathol Lab Med. 2009;133(5):743-755.
7. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28-37. (Pubitemid 43990609)
8. Foroni L, Gerrard G, Nna E, et al. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia. Am J Hematol. 2009;84(8):517-522.
9. Zhang T, Grenier S, Nwachukwu B, Wei C, Lipton JH, Kamel-Reid S. Interlaboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations. J Mol Diagn. 2007;9(4):421-430. (Pubitemid 47434107)
10. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357. (Pubitemid 38072573)
11. Lee JW, Chen Q, Knowles DM, Cesarman E, Wang YL. beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia. J Mol Diagn. 2006;8(3):385-389. (Pubitemid 44063817)
12. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)-a Europe against cancer program. Leukemia. 2003;17(12):2474-2486. (Pubitemid 38072587)
13. Rulcova J, Zmekova V, Zemanova Z, Klamova H, Moravcova J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res. 2007;31(4):483-491. (Pubitemid 46206088)
14. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102(1): 276-283. (Pubitemid 36759665)
15. Stock W, Yu D, Karrison T, et al. Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol. 2006;28(5):1099-1103.
16. Branford S, Cross NC, Hochhaus A, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCRABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006; 20(11):1925-1930. (Pubitemid 44614879)
17. van den Besselaar AM. Standardization of the prothrombin time in oral anticoagulant control. Haemostasis. 1985;15(4):271-277. (Pubitemid 16248327)
18. White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 116(22):e111-e117.
19. Tholen DW. Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline. 2nd ed. Wayne, PA: NCCLS;2004 CLSI document EP5-A2.
20. Krouwer JS. Method Comparison and Bias Estimation Using Patient Sample: Approved Guidelines. 2nd ed. Wayne, PA: NCCLS; 2002. CLSI document EP9-A2.
21. Tholen DW. Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach: Approved Guideline. Wayne, PA: NCCLS;2003 CLSI document EP6-A.
22. Tholen DW. Protocols for Determination of Limits of Detection and Limits of Quantitation: Approved Guideline.Wayne, PA: NCCLS; 2004. CLSI document EP17-A.
23. Statistique-vocabulaire et symboles: Partie 1, Probabilite et termes statistique generaux [Statistics-Vocabulary and Symbols: Part 1, Probability and General Statistical Terms]. 2nd ed. Geneva, Switzerland: ISO; 2006.
24. Krouwer JS. Preliminary Evaluation of Quantitative Clinical Laboratory Methods: Approved Guideline. 2nd ed. Wayne, PA: NCCLS; 2002. CLSI document EP10-A2.
25. Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13(20):6136-6143. (Pubitemid 350075073)
26. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-310. (Pubitemid 16134762)
27. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-3338.
28. Biernaux C, Loos M, Sels A, Huez G, Stryckmans P. Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood. 1995;86(8):3118-3122.
29. Pfaffl MW. A new mathematical model for relative quantification in realtime RT-PCR. Nucleic Acids Res. 2001;29(9):e45.
30. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108(6):1809-1820. (Pubitemid 44394987)